Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum SPDR Series Trust - SPDR S&P Biotech ETF XBI

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests... see more

Bullboard (ARCA:XBI)

View:
1 2 Next
Post by GwenTracyon Apr 13, 2023 4:02am

Kevin Harrington Discusses FSD Pharma

I believe this new product will aid society in reducing the ...more  
69
Post by GwenTracyon Apr 16, 2022 11:15am

FSD Pharma Inc: Lucid MS Video

FSD Pharma is delighted to announce pre-clinical findings ...more  
119
Post by GwenTracyon Apr 09, 2022 12:27pm

FSD: Cancellation of Certain Shares Issued to Former CEO

FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari   TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ...more  
124
Post by GwenTracyon Apr 07, 2022 12:38pm

FSD Pharma Issues Corporate Updates

FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to ...more  
76
Post by GwenTracyon Apr 06, 2022 1:59am

iMining: First Hospital Foundation in Decentraland Metaverse

iMining Enters into Agreement for the First-Ever Hospital Foundation to Be Launched in the Decentraland Metaverse   Vancouver, British Columbia--(Newsfile Corp.) - iMining Technologies Inc ...more  
76
Post by GwenTracyon Feb 04, 2022 11:00am

FSD Pharma Inc: Lucid MS Video

FSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid ...more  
104
Post by GwenTracyon Jan 01, 2022 1:04am

FSD Pharma Announces Share Repurchase Program

FSD Pharma Announces Share Repurchase Program   TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding ...more  
115
Post by GwenTracyon Dec 10, 2021 9:37am

FSD Pharma Establishes New Regulatory Advisory Board

FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members   Regulatory Advisory Board will oversee the drug development ...more  
128
1 2 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities